PRMT5

Across TCGA pan-cancer cohorts, PRMT5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRMT5 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher PRMT5 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PRMT5 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, LUAD, and PDAC are the cancer types where PRMT5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	II,III,IV	0.923	0.469	<.001	37	view →
LUAD	OS	Median	III,IV	1.000	0.663	.007	12	view →
PDAC	DFS	Quartile	II,III,IV	0.536	0.259	.032	2	view →
CCRCC	OS	Median	II,III,IV	0.643	0.839	.028	1	view →
HNSC	OS	Tertile	II,III,IV	1.000	0.943	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PRMT5–LSCC (DFS)

Open the LSCC breakdown →